Dr. Margaret Callahan is the Immunotherapeutics Program Research Director and medical oncologist at Memorial Sloan Kettering Cancer Center. She is one of the two study chairs of the clinical trial “A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab” (NCT01975831).
This study examines combinations of two checkpoint immunotherapies, in patients diagnosed with breast cancer, cervical cancer, colorectal cancer, kidney cancer, and ovarian cancer. One checkpoint inhibitor, durvalumab (Imfinzi™), blocks the PD-L1 pathway, whereas the other, tremelimumab, blocks the CTLA-4 pathway.
Additional investigators working on this trial include:
- Jedd D. Wolchok, M.D., Ph.D. (Memorial Sloan Kettering Cancer Center)
- Kunle Odunsi, M.D., Ph.D. (Roswell Park Cancer Institute)
- Patrick Ott, M.D., Ph.D. (Dana Farber Cancer Institute)
- Antoni Ribas, M.D., Ph.D. (University of California, Los Angeles)
- Patrick Dillon M.D. (University of Virginia Health)
- Mario Sznol, M.D. (Yale University)
- Reva Schneider, M.D. (Mary Crowley Cancer Center)
Projects and Grants
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab (NCT01975831)
Memorial Sloan Kettering Cancer Center | Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Ovarian Cancer | 2013
Let's spread the word about Immunotherapy! Click to share this page with your community.